DXCM · 10-Q · 2026Q3 · Full report
Liquidity and Cash Position
DEXCOM INC · 2026-10-29 · Importance 42 · Surprise 14 · In source text
Cash, cash equivalents, and short-term marketable securities totaled $1.82 billion at September 30, 2026, down $180.8 million from $2.00 billion at December 31, 2025; $1.42 billion, or approximately 78%, was located in the United States. Operating activities generated $1,120.4 million of cash during the first nine months of 2026. The company reported no Credit Facility borrowings, $8.7 million in letters of credit, and $191.3 million available to borrow under the facility, which matures in September 2031. Dexcom reported a 1.74 working capital ratio and a 1.33 quick ratio, and stated its liquidity was sufficient for anticipated requirements for at least the next 12 months.
Key facts
- For the nine months ended September 30, 2026, net cash used in investing activities was $45.4 million, compared with $229.4 million provided in the comparable 2025 period, a $274.8 million decrease. source
- For the nine months ended September 30, 2026, net cash used in financing activities was $1,023.8 million, compared with $164.2 million in the comparable 2025 period, an increase in cash used of $859.6 million. source
- Dexcom's cash, cash equivalents, and short-term marketable securities declined $180.8 million, from $2.00 billion at December 31, 2025 to $1.82 billion at September 30, 2026. source
- Nine-month 2026 investing cash flows included a $289.0 million decrease in net proceeds from marketable securities due to liquidity management and a $41.2 million increase in cash used for a second-quarter 2026 acquisition. source
- Dexcom ended the third quarter of 2026 with cash, cash equivalents, and short-term marketable securities totaling $1.82 billion. source
- Dexcom's cash, cash equivalents, and short-term marketable securities totaled $1.82 billion as of September 30, 2026; $1.42 billion, approximately 78%, was located in the United States, and none was restricted. source
- For the nine months ended September 30, 2026, net cash provided by operating activities was $1,120.4 million, down $26.3 million from $1,146.7 million in the comparable 2025 period. source
- Dexcom had positive operating cash flow of $1.12 billion for the nine months ended September 30, 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | realized | -13.8% | For the nine months ended September 30, 2026, net cash used in financing activities was $1,023.8 million, compared with $164.2 million in… |
| net_income | positive | realized | +11.5% | Dexcom's nine-month 2026 net cash provided by operating activities reflected a $154.7 million increase in net income, a $24.6 million… |
| cash | negative | realized | -4.4% | For the nine months ended September 30, 2026, net cash used in investing activities was $45.4 million, compared with $229.4 million… |
| cash | negative | realized | -2.9% | Dexcom's cash, cash equivalents, and short-term marketable securities declined $180.8 million, from $2.00 billion at December 31, 2025 to… |
| cash | negative | realized | -0.4% | For the nine months ended September 30, 2026, net cash provided by operating activities was $1,120.4 million, down $26.3 million from… |